This filing confirms State Street's continued passive ownership at a stable level. No change in investment thesis; monitor for any future 13D conversion or material stake changes.
IOVA drugs
IOVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $8.08entry
- T+1 · 6d ago +0.12%α −1.20% · $8.09
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
State Street Corp disclosed a 4.8% passive stake in Iovance Biotherapeutics as of September 30, 2026, via a Schedule 13G filing. This is a routine update of its existing passive position, consistent with prior filings, and follows the company's strong Q3 earnings report.
Key Financial Metrics
Key Facts
- State Street Corp reported beneficial ownership of 21,695,003 shares of Iovance common stock as of September 30, 2026.
- The stake represents 4.8% of shares outstanding.
- The filing is a Schedule 13G, certifying passive investment intent with no control or influence purpose.
- State Street has filed multiple prior 13Gs for Iovance, indicating a continuing passive position.
Financial Impact
State Street's stake of 21,695,003 shares is valued at approximately $3.7B market cap * 4.8% = ~$177.6M based on the market data snapshot.
Risk Factors
- No activist intent indicated; passive filing limits immediate market impact.
- Stake is below 5% threshold for mandatory disclosure, suggesting no imminent material change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000677 |
| Document: 0000093751-26-000677-index.html | 0000093751-26-000677 |
| Document: 0000093751-26-000677.txt | 0000093751-26-000677 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers